Literature DB >> 26301053

Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.

Hayato Nakagawa1.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer, and obesity has been established as a risk factor for HCC development. Nonalcoholic steatohepatitis (NASH) is apparently the key link between obesity and hepatocarcinogenesis, and obesity also accelerates HCC development synergistically with other risk factors, such as hepatitis virus infection and alcohol consumption. As an explanation for the pathogenesis of NASH, the so-called "two-hit" theory has been widely accepted, but recently, a better model, the so-called "multiple-hits hypothesis" was proposed, which states that many disease-promoting factors may occur in parallel, rather than consecutively. However, the overall mechanism remains largely unknown. Various cell-cell and organ-organ interactions are involved in the pathogenesis of NASH, and thus appropriate in vivo disease models are essential for a deeper understanding. However, replicating the full spectrum of human NASH has been difficult, as NASH involves obesity, insulin resistance, steatohepatitis, fibrosis, and ultimately HCC, and the lack of an appropriate mouse model has been a considerable barrier to determining the missing links among obesity, NASH, and HCC. In recent years, several innovative mouse models presenting obesity- and NASH-associated HCC have been established by modified diets, chemotoxic agents, genetic manipulation, or a combination of these factors, shedding some light on this complex network and providing new therapeutic strategies. Thus, in this paper, I review the mouse models of obesity- and NASH-associated HCC, especially focusing on recent advances and their clinical relevance.

Entities:  

Keywords:  Hepatocellular carcinoma; Metabolic syndrome; Mouse model; Nonalcoholic steatohepatitis; Obesity

Year:  2015        PMID: 26301053      PMCID: PMC4539404          DOI: 10.4254/wjh.v7.i17.2110

Source DB:  PubMed          Journal:  World J Hepatol


  68 in total

1.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

2.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Authors:  Shu-Hao Hsu; Bo Wang; Janaiah Kota; Jianhua Yu; Stefan Costinean; Huban Kutay; Lianbo Yu; Shoumei Bai; Krista La Perle; Raghu R Chivukula; Hsiaoyin Mao; Min Wei; K Reed Clark; Jerry R Mendell; Michael A Caligiuri; Samson T Jacob; Joshua T Mendell; Kalpana Ghoshal
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

3.  Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.

Authors:  Michiko Itoh; Takayoshi Suganami; Nobutaka Nakagawa; Miyako Tanaka; Yukio Yamamoto; Yasutomi Kamei; Shuji Terai; Isao Sakaida; Yoshihiro Ogawa
Journal:  Am J Pathol       Date:  2011-09-07       Impact factor: 4.307

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 5.  Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Yurie Soejima; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

6.  Plasma levels of adiponectin and primary liver cancer risk in middle-aged Japanese adults with hepatitis virus infection: a nested case-control study.

Authors:  Takehiro Michikawa; Manami Inoue; Norie Sawada; Shizuka Sasazuki; Yasuhito Tanaka; Motoki Iwasaki; Taichi Shimazu; Taiki Yamaji; Masashi Mizokami; Shoichiro Tsugane
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

7.  Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism.

Authors:  C Y Fan; J Pan; N Usuda; A V Yeldandi; M S Rao; J K Reddy
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

8.  Streptozotocin-induced liver tumors in the Syrian hamster.

Authors:  R H Bell; R J Hye; K Miyai
Journal:  Carcinogenesis       Date:  1984-10       Impact factor: 4.944

9.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

10.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

View more
  21 in total

1.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

2.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.

Authors:  Naoto Fujiwara; Hayato Nakagawa; Kenichiro Enooku; Yotaro Kudo; Yuki Hayata; Takuma Nakatsuka; Yasuo Tanaka; Ryosuke Tateishi; Yohko Hikiba; Kento Misumi; Mariko Tanaka; Akimasa Hayashi; Junji Shibahara; Masashi Fukayama; Junichi Arita; Kiyoshi Hasegawa; Hadassa Hirschfield; Yujin Hoshida; Yoshihiro Hirata; Motoyuki Otsuka; Keisuke Tateishi; Kazuhiko Koike
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

3.  Inside-Out or Outside-In: Choosing the Right Model of Hepatocellular Cancer.

Authors:  Satdarshan P Monga
Journal:  Gene Expr       Date:  2020-06-05

4.  Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function.

Authors:  Paweł A Kołodziejski; Ewa Pruszyńska-Oszmałek; Mathias Z Strowski; Krzysztof W Nowak
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

5.  IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma.

Authors:  Turan Aghayev; Aleksandra M Mazitova; Jennifer R Fang; Sergei I Grivennikov; Ekaterina K Koltsova; Iuliia O Peshkova; Matthew Rausch; Manhsin Hung; Kerry F White; Ricard Masia; Elizaveta K Titerina; Aliia R Fatkhullina; Isabelle Cousineau; Simon Turcotte; Dmitry Zhigarev; Anastasiia Marchenko; Svetlana Khoziainova; Petr Makhov; Yin Fei Tan; Andrew V Kossenkov; David L Wiest; John Stagg; Xin Wei Wang; Kerry S Campbell; Amiran K Dzutsev; Giorgio Trinchieri; Jonathan A Hill
Journal:  Cancer Discov       Date:  2022-08-05       Impact factor: 38.272

6.  Integrative genomic analysis of mouse and human hepatocellular carcinoma.

Authors:  Michelle Dow; Rachel M Pyke; Brian Y Tsui; Ludmil B Alexandrov; Hayato Nakagawa; Koji Taniguchi; Ekihiro Seki; Olivier Harismendy; Shabnam Shalapour; Michael Karin; Hannah Carter; Joan Font-Burgada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-04       Impact factor: 11.205

7.  Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors.

Authors:  Marie Liebig; Alireza Hassanzada; Malte Kämmerling; Berit Genz; Brigitte Vollmar; Kerstin Abshagen
Journal:  Exp Biol Med (Maywood)       Date:  2017-10-24

Review 8.  Young Adult Cancer: Influence of the Obesity Pandemic.

Authors:  Nathan A Berger
Journal:  Obesity (Silver Spring)       Date:  2018-04       Impact factor: 5.002

9.  Evaluation of safety for hepatectomy in a novel mouse model with nonalcoholic-steatohepatitis.

Authors:  Yusuke Ozawa; Takafumi Tamura; Yohei Owada; Yoshio Shimizu; Akira Kemmochi; Katsuji Hisakura; Takashi Matsuzaka; Hitoshi Shimano; Hiroko Isoda; Nobuhiro Ohkohchi
Journal:  World J Gastroenterol       Date:  2018-04-21       Impact factor: 5.742

10.  Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver.

Authors:  Indu G Rajapaksha; Lakmie S Gunarathne; Khashayar Asadi; Ross Laybutt; Sof Andrikopoulous; Ian E Alexander; Mathew J Watt; Peter W Angus; Chandana B Herath
Journal:  Hepatol Commun       Date:  2021-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.